Detomidine is under clinical development by Clexio Biosciences and currently in Phase II for Pruritus. According to GlobalData, Phase II drugs for Pruritus have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Detomidine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Detomidine overview
Detomidine (CLE-400) is under development for the treatment of post-operative pain, peripheral neuropathic pain, chronic pruritus in patients with notalgia paresthetica (NP) and brachioradial pruritus (BRP). It is administered by topical route and formulated in the form of gel. The drug candidate acts by targeting the alpha2 adrenergic receptor. It was also under development for the treatment of painful diabetic neuropathy.
Clexio Biosciences overview
Clexio Biosciences (Clexio) is a clinical-stage pharmaceutical company focused on the development of novel drugs, small molecules, and drug-device combinations for the treatment of pain, depression, and other central nervous system (CNS) indications. Its pipeline product portfolio includes CLE-100, an oral NMDA receptor modulator for adjunctive therapy in major depressive disorder. The company’s other pipelines include CLE-900 and CLE-400, a topical formulation for the treatment of PDN, and CLE-500, a patient-controlled drug-device combination for immediate relief of cluster headaches. It utilizes its OLAR Oral Long Acting Release platform to enable continuous drug delivery to the GI tract, allowing for more efficient drug absorption and lower drug plasma fluctuations. Clexio is headquartered in Jerusalem, Israel.
For a complete picture of Detomidine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
